Israel Englander’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.66M | Sell |
1,154,228
-2,280,221
| -66% | -$20.8M | ﹤0.01% | 2314 |
|
|
2026
Q1 | $30.9M | Buy |
3,434,449
+2,764,778
| +413% | +$43.6M | 0.01% | 1204 |
|
|
2025
Q4 | $12.2M | Buy |
669,671
+384,832
| +135% | +$6.49M | 0.01% | 2047 |
|
|
2025
Q3 | $4.18M | Sell |
284,839
-850,917
| -75% | -$14.6M | ﹤0.01% | 3330 |
|
|
2025
Q2 | $20.7M | Sell |
1,135,756
-1,010,553
| -47% | -$20.6M | 0.01% | 1538 |
|
|
2025
Q1 | $42.6M | Buy |
2,146,309
+986,776
| +85% | +$17.1M | 0.02% | 886 |
|
|
2024
Q4 | $19.9M | Buy |
1,159,533
+42,603
| +4% | +$801K | 0.01% | 1523 |
|
|
2024
Q3 | $22.3M | Buy |
1,116,930
+176,275
| +19% | +$2.74M | 0.01% | 1451 |
|
|
2024
Q2 | $10.5M | Sell |
940,655
-769,366
| -45% | -$6.45M | ﹤0.01% | 2034 |
|
|
2024
Q1 | $11.3M | Sell |
1,710,021
-1,741,846
| -50% | -$9.52M | ﹤0.01% | 2072 |
|
|
2023
Q4 | $15.6M | Sell |
3,451,867
-642,373
| -16% | -$2.38M | 0.01% | 1764 |
|
|
2023
Q3 | $14.7M | Buy |
4,094,240
+1,184,054
| +41% | +$4.56M | 0.01% | 1697 |
|
|
2023
Q2 | $10.7M | Sell |
2,910,186
-2,463,315
| -46% | -$9.13M | 0.01% | 1956 |
|
|
2023
Q1 | $17.8M | Buy |
5,373,501
+76,720
| +1% | +$265K | 0.01% | 1426 |
|
|
2022
Q4 | $20.6M | Buy |
5,296,781
+3,569,778
| +207% | +$11M | 0.01% | 1427 |
|
|
2022
Q3 | $4.2M | Sell |
1,727,003
-4,162,968
| -71% | -$9.99M | ﹤0.01% | 3065 |
|
|
2022
Q2 | $11.7M | Buy |
5,889,971
+2,531,272
| +75% | +$4.98M | 0.01% | 1849 |
|
|
2022
Q1 | $6.15M | Buy |
3,358,699
+3,189,501
| +1,885% | +$4.98M | ﹤0.01% | 2701 |
|
|
2021
Q4 | $239K | Sell |
169,198
-412,419
| -71% | -$542K | ﹤0.01% | 5755 |
|
|
2021
Q3 | $657K | Sell |
581,617
-420,519
| -42% | -$589K | ﹤0.01% | 5086 |
|
|
2021
Q2 | $1.6M | Buy |
+1,002,136
| New | +$1.76M | ﹤0.01% | 4207 |
|
|
2021
Q1 | – | Sell |
-52,264
| Closed | -$102K | – | 5843 |
|
|
2020
Q4 | $102K | Buy |
52,264
+20,517
| +65% | +$43.1K | ﹤0.01% | 5018 |
|
|
2020
Q3 | $76 | Sell |
31,747
-291,080
| -90% | -$798K | ﹤0.01% | 4256 |
|
|
2020
Q2 | $946K | Buy |
322,827
+128,725
| +66% | +$370K | ﹤0.01% | 3030 |
|
|
2020
Q1 | $559K | Sell |
194,102
-71,999
| -27% | -$249K | ﹤0.01% | 2817 |
|
|
2019
Q4 | $1.06M | Sell |
266,101
-596,418
| -69% | -$2.6M | ﹤0.01% | 2976 |
|
|
2019
Q3 | $3.84M | Buy |
862,519
+743,506
| +625% | +$3.11M | 0.01% | 2006 |
|
|
2019
Q2 | $461K | Buy |
+119,013
| New | +$525K | ﹤0.01% | 3294 |
|
|
2018
Q3 | – | Sell |
-229,416
| Closed | -$1.03M | – | 3851 |
|
|
2018
Q2 | $1.03M | Sell |
229,416
-44,205
| -16% | -$220K | ﹤0.01% | 2815 |
|
|
2018
Q1 | $1.26M | Buy |
273,621
+206,088
| +305% | +$819K | ﹤0.01% | 2577 |
|
|
2017
Q4 | $217K | Buy |
67,533
+48,455
| +254% | +$136K | ﹤0.01% | 3495 |
|
|
2017
Q3 | $59K | Buy |
+19,078
| New | +$63.5K | ﹤0.01% | 3396 |
|
Other funds holding ADMA
RCMNY
CP
Israel Englander's ADMA Position: Q2 2026 in Review
Israel Englander reduced its ADMA Biologics (ADMA) stake by 66% in Q2 2026, selling an estimated $20.8M and leaving 1,154,228 shares worth $9.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2314.
Israel Englander first reported a position in ADMA in Q3 2017 and has held it in 32 quarters since. The position peaked at $42.6M in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- Israel Englander held 1,154,228 shares of ADMA Biologics worth $9.66M as of Q2 2026.
- Israel Englander sold 2,280,221 ADMA Biologics shares in Q2 2026, an estimated $20.8M.
- ADMA Biologics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2314 holding.
- Israel Englander first reported a position in ADMA Biologics in Q3 2017 and has held it in 32 quarters since.
- Israel Englander's ADMA Biologics position peaked at $42.6M in Q1 2025.
- 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.